© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Chronic Lymphocytic Leukemia
Acalabrutinib Appears Tolerable in Chronic Lymphocytic Leukemia
April 02, 2020
Jeff P. Sharman, MD, discusses the secondary end points from the phase III ELEVATE-TN trial, which evaluated the role of acalabrutinib, either as a single agent or in combination with obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.
Positive Efficacy Achieved With Bendamustine Debulking Followed by Ofatumumab /Ibrutinib in CLL
March 19, 2020
Bendamustine debulking followed by ofatumumab and ibrutinib demonstrated an overall response rate of 92% in patients with chronic lymphocytic leukemia, meeting the primary end point of the phase II CLL2-BIO trial, and was well-tolerated with no new safety signals. Results from the study were published in Haematologica.
Current Regimens Being Investigated in Chronic Lymphocytic Leukemia
March 05, 2020
Alexey V. Danilov, MD, PhD, discusses important studies in the chronic lymphocytic leukemia space and questions whether combination or sequential therapy is better for patients with chronic lymphocytic leukemia.
The Role of BTK Inhibitors Evolve for the Treatment of Patients With CLL
March 05, 2020
In an interview with Targeted Oncology, Alexey V. Danilov, MD, PhD, discussed the ELEVATE-TN trial and other potentially practice-changing BTK inhibitor combinations expected to emerge in chronic lymphocytic leukemia.
Bruton Tyrosine Kinase Inhibitors Signal Promise in the Treatment of Chronic Lymphocytic Leukemia
February 18, 2020
The use of agents targeting Bruton tyrosine kinase have moved into the standard of care for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma in recent years. New data have indicated that more effective therapy by way of combination regimens and newly approved agents may further improve the prognosis of this disease.
Adverse Events Differ Among BTK Inhibitors in CLL
February 14, 2020
Jeff P. Sharman, MD, discusses what differentiates acalabrutinib from other BTK inhibitors available in chronic lymphocytic leukemia.
Predictive Value of Select Gene Mutations Demonstrated in Phase III CLL Study
February 11, 2020
Next-generation sequencing in patients with chronic lymphocytic leukemia treated with the combination of chlorambucil and ofatumumab showed that the presence of TP53, SF3B1, and NOTCH1 mutations were predictive of reduced efficacy, according to the results of the phase III COMPLEMENT1 trial published in Haematologica.
Novel Triplet Regimen Induces Promising Early Activity in Relapsed/Refractory CLL
January 31, 2020
In an interview with Targeted Oncology, Paul M. Barr, MD, discussed the rationale and preliminary findings for the phase I/II study evaluating umbralisib and ublituximab plus venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia. He also explained how the role of combination therapy continues to evolve in this space.
Clinical Cases in Chronic Lymphocytic Leukemia
January 28, 2020